Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CSL ( (AU:CSL) ) has issued an update.
CSL Limited announced a change in the director’s interest, with Dr. Brian Daniels acquiring 1,700 American Depositary Receipts (ADRs), representing 3,400 ordinary shares in the company. This on-market purchase reflects an increase in Dr. Daniels’ indirect interest in CSL, potentially signaling confidence in the company’s future performance and stability, which could positively impact stakeholder perception.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$225.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, specializing in the development and manufacturing of innovative biotherapies and influenza vaccines. The company is a global leader in plasma-derived therapies and has a significant market focus on providing life-saving medicines to patients with rare and serious diseases.
YTD Price Performance: -35.23%
Average Trading Volume: 1,213,654
Technical Sentiment Signal: Sell
Current Market Cap: A$86.77B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.